Back to results
US 2017/0304230 A1Published application
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Claims30
A method of increasing metabolic lifetime of dextromethorphan, comprising co-administering to a human being a combination of:
- a. a bupropion;
- with
- b. a dextromethorphan;
- wherein the human subject is an extensive metabolizer of dextromethorphan;
- wherein a dosage form comprising the bupropion and the dextromethorphan is administered once a day for one to eight consecutive days and twice a day thereafter for at least consecutive 30 days;
- wherein the dosage form comprises from about 50 mg to about 130 mg of the bupropion;
- and
- wherein, on the tenth day the dosage form is administered, the plasma trough level of the dextromethorphan is increased at least 15-fold over the plasma trough level of the dextromethorphan achieved by administering the same amount of the dextromethorphan without the bupropion.
5 more elements
A method of increasing metabolic lifetime of dextromethorphan, comprising co-administering to a human being a combination of:
- a. a bupropion;
- with
- b. at least about 42 mg of a dextromethorphan;
- wherein the human subject is an extensive metabolizer of the dextromethorphan;
- wherein a dosage form comprising the bupropion and the dextromethorphan is administered once a day for one to eight consecutive days and twice a day thereafter for at least consecutive 30 days;
- wherein, on the tenth day the dosage form is administered, the plasma trough level of the dextromethorphan is increased at least 15-fold over the plasma trough level of the dextromethorphan achieved by administering the same amount of the dextromethorphan without the bupropion.
3 more elements
Dependencies are inferred from the claim text.